Abemaciclib in combination with fulvestrant FDA approved for HR+, HER2- advanced or metastatic breast cancer progressing following endocrine therapy

Non-Sponsored Content

By: scienterrific | Last updated: 28 September 2017 | In: US FDA Onc\Haem Approvals, Uncategorised

Article Keywords

AstraZeneca, Verzenio, AZ, Faslodex, CDK46, HER2, HR, Eli Lilly, FDA, fulvestrant, abemaciclib

On 28 September 2017, the FDA approved abemaciclib (Verzenio®, Eli Lilly and Company) in combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

Non-Sponsored Content